You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

TRICOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Tricor, and when can generic versions of Tricor launch?

Tricor is a drug marketed by Abbvie and is included in three NDAs.

The generic ingredient in TRICOR is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tricor

A generic version of TRICOR was approved as fenofibrate by RHODES PHARMS on May 13th, 2005.

  Try a Trial

Drug patent expirations by year for TRICOR
Drug Prices for TRICOR

See drug prices for TRICOR

Drug Sales Revenue Trends for TRICOR

See drug sales revenues for TRICOR

Recent Clinical Trials for TRICOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The University of Texas Medical Branch, GalvestonPhase 2/Phase 3
Shriners Hospitals for ChildrenPhase 2/Phase 3
National Institute of General Medical Sciences (NIGMS)Phase 2/Phase 3

See all TRICOR clinical trials

Pharmacology for TRICOR
Anatomical Therapeutic Chemical (ATC) Classes for TRICOR
Paragraph IV (Patent) Challenges for TRICOR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TRICOR Tablets fenofibrate 48 mg 021656 1 2008-07-01
TRICOR Tablets fenofibrate 145 mg 021656 1 2007-10-19

US Patents and Regulatory Information for TRICOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie TRICOR (MICRONIZED) fenofibrate CAPSULE;ORAL 019304-004 Jun 30, 1999 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021203-003 Sep 4, 2001 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021203-001 Sep 4, 2001 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRICOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 ⤷  Try a Trial ⤷  Try a Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021203-003 Sep 4, 2001 ⤷  Try a Trial ⤷  Try a Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021203-003 Sep 4, 2001 ⤷  Try a Trial ⤷  Try a Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.